RT Journal Article
T1 Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients With Low Cardiac Output Syndrome After Cardiac Surgery: Clinical Trial FIM-BGC-2014-01.
A1 Guerrero-Orriach, Jose L
A1 Malo-Manso, Alfredo
A1 Ramirez-Aliaga, Marta
A1 Florez Vela, Ana Isabel
A1 Galán-Ortega, Manuel
A1 Moreno-Cortes, Isabel
A1 Gonzalez-Almendros, Inmaculada
A1 Ramirez-Fernandez, Alicia
A1 Ariza-Villanueva, Daniel
A1 Escalona-Belmonte, Juan Jose
A1 Quesada-Muñoz, Guillermo
A1 Sepúlveda-Haro, Enrique
A1 Romero-Molina, Salvador
A1 Bellido-Estevez, Inmaculada
A1 Gomez-Luque, Aurelio
A1 Rubio-Navarro, Manuel
A1 Alcaide-Torres, Juan
A1 Santiago-Fernandez, Concepcion
A1 Garrido-Sanchez, Lourdes
A1 Cruz-Mañas, Jose
K1 cardiac surgery
K1 dobutamine
K1 kidney
K1 levosimendan
K1 low cardiac output
AB Low-cardiac output syndrome (LCOS) after cardiac surgery secondary to systemic hypoperfusion is associated with a higher incidence of renal and neurological damage. A range of effective therapies are available for LCOS. The beneficial systemic effects of levosimendan persist even after cardiac output is restored, which suggests an independent cardioprotective effect. A double-blind clinical trial was conducted in patients with a confirmed diagnosis of LCOS randomized into two treatment groups (levosimendan vs. dobutamine). Monitoring of hemodynamic (cardiac index, systolic volume index, heart rate, mean arterial pressure, central venous pressure, central venous saturation); biochemical (e.g. creatinine, S100B protein, NT-proBNP, troponin I); and renal parameters was performed using acute kidney injury scale (AKI scale) and renal and brain ultrasound measurements [vascular resistance index (VRI)] at diagnosis and during the first 48 h. Significant differences were observed between groups in terms of cardiac index, systolic volume index, NT-proBNP, and kidney injury stage at diagnosis. In the levosimendan group, there were significant variations in AKI stage after 24 and 48 h. No significant differences were observed in the other parameters studied. Levosimendan showed a beneficial effect on renal function in LCOS patients after cardiac surgery that was independent from cardiac output and vascular tone. This effect is probably achieved by pharmacological postconditioning. EUDRA CT, identifier 2014-001461-27. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001461-27.
SN 1663-9812
YR 2020
FD 2020-08-26
LK http://hdl.handle.net/10668/16327
UL http://hdl.handle.net/10668/16327
LA en
DS RISalud
RD Apr 6, 2025